Literature review · Immune & inflammation

KPV

KPV has mechanistic cell and mouse-colitis evidence. The cited work is preclinical and does not establish a treatment for inflammatory bowel disease or a general immune benefit in people.

By HeartPep · Reviewed · 1 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The selected paper examines how peptide transport relates to inflammatory signalling, using human-derived cell lines and two chemically induced mouse-colitis models. Human-origin cells do not make an experiment a human clinical trial.

Identity & scope

KPV denotes the Lys-Pro-Val tripeptide in the cited experiments. An exact molecular identity and relevant laboratory specification would still need confirmation for any supplied sample.

Catalogue labels covered: KPV.

What the research shows

  • Dalmasso and colleagues linked cellular KPV uptake with the PepT1 transporter.
  • Inflammatory signalling, cytokine and tissue outcomes changed in the tested cell and mouse models.

Critical interpretation

Why the transport mechanism matters

The central mechanistic question is not simply whether an inflammatory marker falls after exposure. It is whether cellular entry is needed for that response. Comparing transporter-expressing systems and competing substrates helps make this a testable explanation. Our interpretation is that such experiments strengthen a mechanism within the model, while leaving open whether the same transport conditions occur at a proposed human site of action. [1]

Two mouse models are not two clinical populations

Using more than one induced-colitis model can test whether a finding depends entirely on one experimental insult. It does not recreate the heterogeneous causes, chronic course and concurrent treatments of human inflammatory disease. A translational study would need to define exposure and a disease-relevant outcome, rather than assume that reduced model inflammation establishes clinical remission. [1]

How to read a sparse evidence base

One mechanistic paper can be useful for forming an experiment, but cannot estimate rare harms, long-term outcomes or the reproducibility of an entire field. Absence of a human trial in this selected entry is a coverage limit, not proof that no research exists. Stronger evidence would require independent replication and appropriately controlled human investigation before clinical conclusions. [1]

Limitations & uncertainties

  • Cell-line signalling and chemically induced disease models may not reproduce human disease or exposure.
  • The paper is not evidence of clinical symptom relief, remission or long-term human safety.
  • The publication does not authenticate the identity, content or suitability of a HeartPep vial.

Open research questions

  • Can independent experiments reproduce the transport-dependent effects across relevant models?
  • Which controlled human studies could test translation without assuming it from the mouse findings?

Selected papers & source records

Download bibliography
Animal studyNamed compoundFull text consulted

1. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (opens in a new tab)

Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. (2008). Gastroenterology. DOI: 10.1053/j.gastro.2007.10.026 (opens in a new tab) · PMID 18061177

Design & population
Human epithelial/T-cell lines and DSS- and TNBS-induced colitis models in mice, studying transport and inflammatory pathways.
What the study found
Reported PepT1-associated uptake, reduced inflammatory signalling and lower inflammation in the tested mouse models.
Limits on interpretation
Preclinical study with no human treatment arm. Findings do not establish efficacy or safety in inflammatory bowel disease patients.

Search & review scope

Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.

One selected primary mechanistic paper; accessible full-text discussion and transport experiments were consulted. No comprehensive human-trial or unpublished-data search.

Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.

Recorded search terms
  • 18061177 KPV PepT1 colitis Dalmasso
  • "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation" doi authors
  • "10.1053/j.gastro.2007.10.026" correction retraction

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. KPV: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/kpv.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes